Carcinoma, Non-Small-Cell Lung
Why trials studying Carcinoma, Non-Small-Cell Lung stopped, in this sample of ClinicalTrials.gov.
18 stopped trials with a clear reason; 78% ended for non-scientific reasons.
| Reason | Trials | Share |
|---|---|---|
| funding business | 7 | 39% |
| safety | 3 | 17% |
| regulatory | 3 | 17% |
| slow accrual | 3 | 17% |
| futility | 1 | 6% |
| logistics pi | 1 | 6% |
Trials
- A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
NCT06704724 · TERMINATED · funding business
“The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns.” - A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC
NCT06280196 · TERMINATED · regulatory
“The new regulatory developments have led us to conclude that a Phase 3 study is no longer necessary for the development and approval of BAT3306. As such, to ensure effective use of clinical resources, we are terminating this study.” - Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI
NCT05302817 · TERMINATED · regulatory
“Regulatory compliance.” - A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
NCT05397171 · TERMINATED · safety
“This study was terminated early as per protocol Section 4.4, based on overall risk-benefit profile observed to date. No safety concerns reported. Only Substudy 1 Part A was started; Parts B \& C were not started. Entire Master Protocol was terminated.” - (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
NCT05153408 · TERMINATED · futility
“Lack of efficacy” - Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects
NCT04515979 · TERMINATED · funding business
“This is because Medpacto decided to modify its development strategy as the business and development environment changed.” - Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
NCT04427072 · TERMINATED · funding business
“Company decision not related to any safety concerns.” - Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations
NCT04323436 · TERMINATED · funding business
“Study termination based on sponsor decision due to lack of tolerability observed with capmatinib and spartalizumab combination treatment when compared to data from capmatinib single agent studies” - A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT04222972 · TERMINATED · funding business
“Early termination of the study resulted from organizational and commercial decisions that led to the discontinuation of pralsetinib's global marketing and development in all territories (excluding US and Greater China).” - Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients.
NCT03460678 · TERMINATED · slow accrual
“Difficulty recruiting” - Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer
NCT03030131 · TERMINATED · safety
“Definitive discontinuation according to safety monitoring of death from the 46th patient onwards.” - Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
NCT02954991 · TERMINATED · funding business
“This study was terminated as a result of Sponsor portfolio reprioritization.” - Safety & Immunogenicity of JNJ-64041757, Live-attenuated Double-deleted Listeria Immunotherapy, in Subjects With Non Small Cell Lung Cancer
NCT02592967 · TERMINATED · funding business
“Development of JNJ-64041757 discontinued due to lack of efficacy. No further follow up data will be collected after October 22, 2018.” - A Randomized Trial to Study the Safety and Efficacy of EGF Cancer Vaccination in Late-stage (IIIB/IV) Non-small Cell Lung Cancer Patients
NCT01444118 · TERMINATED · safety
“The early termination is not related to safety/toxicity but to initiate new Phase III with biomarker to enrich population \& to further strengthen OS benefit” - Role of a Silicone Prosthesis to Prevent Airway Obstruction Recurrence in Lung Cancers
NCT01064050 · TERMINATED · slow accrual
“Difficulty to include patient” - Efficacy Study of Induction Chemotherapy Before Surgery in Operable Non-small Cell Lung Cancer
NCT00329472 · WITHDRAWN · slow accrual
“poor enrollment” - Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy
NCT00290017 · TERMINATED · regulatory
“FDA Hold May 2007” - Concomitant Chemo-radiotherapy in Locally Advanced Non Small Cell Lung Cancer
NCT00210171 · WITHDRAWN · logistics pi
“The study was withdrawn due to logistic issues.”
Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.